

IFW



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83930

Naonori IMAZAKI, et al.

Appln. No.: 10/509,897

Group Art Unit: 1614

Confirmation No.: 1034

Examiner: Unassigned

Filed: October 1, 2004

For: BENZAMIDE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. XP-002419112, (Database CA - Chemical Abstracts Service).
2. Canadian Patent No. 2 386 387 A1, published April 12, 2001 to Takeda Chemical Industries.
3. H. Bader et al., "Nucleophilic Displacements of Activated Fluorine in Aromatic Compounds", Journal of Organic Chemistry, American Chemical Society, Vol. 31, July 1966, pp. 2319-2321.

Naonori IMAZAKI, et al.
U.S. Appl. No.: 10/509,897
INFORMATION DISCLOSURE STATEMENT

4. Canadian Patent No. 2 403 321 A1, published September 20, 2001 to Mitsubishi Pharma Corporation.


One copy of each of the listed documents are submitted herewith, along with a copy of the corresponding Supplementary Partial European Search Report dated February 22, 2007, citing such documents and indicating the degree of relevance found by the foreign patent office.

The present Information Disclosure Statement is being filed thirty days or fewer from the communication from a foreign patent office and a Statement Under 37 C.F.R. §1.704(d) is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 23, 2007



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83930

Naonori IMAZAKI, et al.

Appln. No.: 10/509,897

Group Art Unit: 1614

Confirmation No.: 1034

Examiner: Unassigned

Filed: October 1, 2004

For: BENZAMIDE DERIVATIVES

STATEMENT UNDER 37 C.F.R. § 1.704(d)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 23, 2007

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

MAR 23 2007

Complete if Known

Application Number	10/509,897
Confirmation Number	1034
Filing Date	October 1, 2004
First Named Inventor	Naonori IMAZAKI
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	Q83930

Sheet 1 of

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		CA	2 386 387	A1	04/12/2001	Takeda Chemical Industries	
		CA	2 403 321	A1	09/20/2001	Mitsubishi Pharma Corporation	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		XP-002419112, (Database CA - Chemical Abstracts Service).	
		H. Bader et al., "Nucleophilic Displacements of Activated Fluorine in Aromatic Compounds", Journal of Organic Chemistry, American Chemical Society, Vol. 31, July 1966, pp. 2319-2321.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.